TABLE 3.
Active clinical development programs for the pharmacological treatment of hearing loss Current development programs of drug candidates for the treatment of hearing loss (where “in development” is defined as, at minimum, a disclosed, identified target in active development) were identified in the drugs database of global data (January 2024 cutoff) and cross-referenced with company websites. Gene therapy is excluded.
| Company | Hearing Loss Indication | Brand or Drug Name (Active Principle) |
Highest Active Development Stage |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. | Cisplatin-induced ototoxicity (pediatric) | Pedmarky (sodium thiosulfate) |
Marketed |
| Sound Pharmaceuticals Inc. | Ménière’s disease/aminoglycoside-induced ototoxicity | SPI-1005/SPI-3005 (ebselen) |
Phase III/II |
| Acousia Therapeutics GmbH | Cisplatin-induced ototoxicity | ACOU085 | Phase II |
| AudioCure Pharma GmbH | Idiopathic sudden SNHL | AC-102 | Phase II |
| Gateway Biotechnology Inc. | NIHL | GW-HP1 (zonisamide) |
Phase II |
| Nobelpharma Co Ltd | Pendred syndrome/DFNB4 (hearing loss) | NPC-12 (sirolimus) |
Phase II |
| Sensorion SA | Sudden SNHL/cisplatin-induced ototoxicity/hearing preservation after cochlear implantation | SENS-401 (arazasetron) |
Phase II |
| Spiral Therapeutics Inc. | Ménière’s disease | SPT-2101 (dexamethasone) |
Phase I |
| Audion Therapeutics BV | SNHL | AUD-1001 (LY-3056480) |
Phase I |
| IMD Farm Co Ltd | SNHL | IMDSST-03 | Phase I |
| Otologic Pharmaceuticals Inc. | SNHL | NHPN-1010 (acetylcysteine + disufenton sodium) |
Phase I |
| Regeneron Pharmaceuticals Inc. | Cisplatin-induced ototoxicity | DB-020 (sodium thiosulfate) |
Phase I |
NIH, noise-induced hearing loss; SNHL, sensorineural hearing loss.